SG Americas Securities LLC Has $17.98 Million Stock Holdings in IQVIA Holdings Inc. $IQV

SG Americas Securities LLC trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 67.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 114,060 shares of the medical research company’s stock after selling 233,143 shares during the period. SG Americas Securities LLC owned 0.07% of IQVIA worth $17,975,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Pacer Advisors Inc. increased its position in IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock worth $153,681,000 after buying an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock worth $448,686,000 after purchasing an additional 798,534 shares during the last quarter. Nordea Investment Management AB grew its holdings in IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after purchasing an additional 606,391 shares during the last quarter. Hawk Ridge Capital Management LP bought a new position in shares of IQVIA in the first quarter valued at approximately $77,096,000. Finally, Nuveen LLC acquired a new stake in shares of IQVIA in the first quarter worth $76,328,000. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IQV. Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. UBS Group lifted their price objective on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Citigroup increased their target price on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th. Stifel Nicolaus lifted their price target on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Truist Financial reissued a “buy” rating and issued a $265.00 price objective (up from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $241.00.

IQVIA Stock Performance

IQV opened at $221.06 on Friday. The stock has a market cap of $37.65 billion, a PE ratio of 30.32, a P/E/G ratio of 2.47 and a beta of 1.34. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $228.12. The stock’s 50 day simple moving average is $202.72 and its 200-day simple moving average is $178.71. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the previous year, the company earned $2.84 earnings per share. The business’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.